Stemline Therapeutics (STML) Files $50M IPO

April 2, 2012 4:12 PM EDT Send to a Friend
In a Form S-1 late Monday, Stemline Therapeutics (Nasdaq: STML) registered a $50 million initial public offering. The company plans to list on the NASDAQ under the symbol "STML."

The offering is being made through Oppenheimer and JMP Securities.

Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

IPOs

Related Entities

JMP Securities, S1

Add Your Comment